Gene · 5598
Papers3,971
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 3,971
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Licochalcone B targets neural cell adhesion molecule 1 to inhibit osteosarcoma progression and ferroptosis resistance via extracellular signal-regulated kinase 5 and nuclear factor kappa B pathways. | Phytomedicine | 2026 | 41349457 | PubTator, text mining | PubMed |
| Modulation of mitochondrial dysfunction: Mechanisms and strategies for the use of natural products to treat stroke. | Neural Regen Res | 2026 | 40618255 | PubTator, text mining | PubMed |
| Mechanistic study of glutamine metabolic reprogramming driving non-small cell lung cancer progression via the FGF17-FGFR4 axis mediating epithelial-mesenchymal transition. | Front Mol Biosci | 2025 | 41551579 | PubTator, text mining | PubMed |
| Coupling the MAPK Slt2/ERK1 Pathway and IRE1-driven UPR Through Transcription Factor Rlm1/MEF2. | Res Sq | 2025 | 41510289 | PubTator, text mining | PubMed |
| Integration of human ERKs and DUSPs into the yeast cell wall integrity pathway. | Sci Rep | 2025 | 41453955 | PubTator, text mining | PubMed |
| Targeting DDOST improves the efficacy of lenvatinib and immunotherapy in hepatocellular carcinoma. | Exp Mol Med | 2025 | 41413687 | PubTator, text mining | PubMed |
| Protein Posttranslational Modifications in Glioma Stem Cells. | Biol Pharm Bull | 2025 | 41320273 | PubTator, text mining | PubMed |
| Genomic and Demographic Characteristics of Angiosarcoma as Described in the AACR Project GENIE Registry. | Cancers (Basel) | 2025 | 41301029 | PubTator, text mining | PubMed |
| Specific transcriptional signature dataset of extracellular signal-regulated kinase 5 in leiomyosarcoma derived cell lines. | BMC Res Notes | 2025 | 41233882 | PubTator, text mining | PubMed |
| The Discovery of Small ERK5 Inhibitors via Structure-Based Virtual Screening, Biological Evaluation and MD Simulations. | Molecules | 2025 | 41226144 | PubTator, text mining | PubMed |
| Investigating the Roles of MAPKs as Precision Oncology Targets: A Multi-cancer Expression and Survival Study. | Cancer Genomics Proteomics | 2025 | 41151853 | PubTator, text mining | PubMed |
| NADPH oxidase 2 inhibitor GSK2795039 exerts antiplatelet and antithrombotic activity. | Sci Rep | 2025 | 41102391 | PubTator, text mining | PubMed |
| Microplastics as emerging carcinogens: from environmental pollutants to oncogenic drivers. | Mol Cancer | 2025 | 41063167 | PubTator, text mining | PubMed |
| Altered venous flow drives endothelial to mesenchymal transition in varicose veins by suppressing PIEZO1-KLF2 signaling. | Cell Mol Life Sci | 2025 | 41055734 | PubTator, text mining | PubMed |
| MEK5/ERK5 inhibition sensitizes NRAS-mutant melanoma to MAPK-targeted therapy by preventing Cyclin D/CDK4-mediated G1/S progression. | Cell Death Dis | 2025 | 41053077 | PubTator, text mining | PubMed |
| Navigating the Landscape of Exosomal microRNAs: Charting Their Pivotal Role as Biomarkers in Hematological Malignancies. | Noncoding RNA | 2025 | 40981381 | PubTator, text mining | PubMed |
| Novel Tricyclic Compounds as ERK5 Inhibitors for Treating Cancer. | ACS Med Chem Lett | 2025 | 40959256 | PubTator, text mining | PubMed |
| Dual-Specificity Protein Phosphatases Targeting Extracellular Signal-Regulated Kinases: Friends or Foes in the Biology of Cancer? | Int J Mol Sci | 2025 | 40943262 | PubTator, text mining | PubMed |
| Advances in ERK1/2 inhibition: a medicinal chemistry perspective on structure and regulation. | J Enzyme Inhib Med Chem | 2025 | 40928301 | PubTator, text mining | PubMed |
| Impacts of aging and fluid shear stress on vascular endothelial metabolism and atherosclerosis development. | J Biomed Sci | 2025 | 40890841 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5598/papers?page=4